Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.
| Revenue (Most Recent Fiscal Year) | $39.01M |
| Net Income (Most Recent Fiscal Year) | $-3.82M |
| PE Ratio (Current Year Earnings Estimate) | 46.15 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 10.50 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 20.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -9.30% |
| Net Margin (Trailing 12 Months) | -9.49% |
| Return on Equity (Trailing 12 Months) | -3.15% |
| Return on Assets (Trailing 12 Months) | -1.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.23 |
| Inventory Turnover (Trailing 12 Months) | 2.44 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 26.82M |
| Free Float | 22.52M |
| Market Capitalization | $507.39M |
| Average Volume (Last 20 Days) | 0.34M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.03% |
| Percentage Held By Institutions (Latest 13F Reports) | 27.86% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |